FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...

DLL3 expression on circulating tumor cells may predict Imdelltra response in small cell lung cancer patients, aiding personalized treatment decisions. High DLL3 expression correlates with positive ...

A new test for breast cancer patients has been developed which can predict whether or not their cancer is likely to return just two weeks after they start treatment. Experts said thousands of breast ...

Hepatitis C is a tiny virus with a significant impact. It's a small RNA virus that spreads through the blood and infects the liver. Even though today's medicines can cure it, hepatitis C remains a ...

British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England. 2014 File Photo / Agence France-Presse CHICAGO — Treating breast cancer patients with AstraZeneca’s ...

In the continuing evolution of personalized medicine, a new study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with ...

Credit: Getty Images. Starting treatment for advanced NSCLC before receiving genomic test results compromises patient outcomes, a study suggests. Starting treatment for advanced non-small cell lung ...

Add Yahoo as a preferred source to see more of our stories on Google. A new rapid test could improve treatment of urinary tract infections, by identifying the most effective antibiotic for each ...

A new rapid test could improve treatment of urinary tract infections, by identifying the most effective antibiotic for each individual patient. The test applies different antibiotics to bacteria found ...